Objective To compare the incidence, severity, and clinical course of frequently reported
adverse events (AEs) after treatment with smoking cessation pharmacotherapies. Methods …

Tobacco use is the leading cause of preventable death and disability in the world. Although
gradually declining in most developed countries, the prevalence of tobacco use has …

Abstract Introduction The British Columbia Ministry of Health launched a Smoking Cessation
Program on September 30, 2011, providing financial coverage for smoking cessation …

Smoking continues to be the leading cause of preventable deaths in the USA, accounting for
one in every five deaths every year, and cardiovascular (CV) disease remains the leading …

Introduction This study sought to compare medication efficacy in participants with medical
comorbidities who smoke in the Evaluating Adverse Events in a Global Smoking Cessation …

Background Two treatments for smoking cessation—varenicline and bupropion—carry
Boxed Warnings from the US Food and Drug Administration (FDA) about suicidal/self …

Abstract Background Bupropion hydrochloride (Zyban) is an effective aid to smoking
cessation; however, its use has previously been associated with neuropsychiatric adverse …

Objectives: Several smoking cessation treatments (nicotine replacement therapy and non-
nicotine prescription medication) and electronic cigarettes are widely used. We evaluated …

Abstract Background Bupropion (Zyban) is the first new pharmacological treatment for
smoking cessation to be introduced since nicotine replacement therapy. In smoking …

Abstract Background and Aims Analysed using classical frequentist hypothesis testing with
alpha set to 0.05, the Evaluating Adverse Events in a Global Smoking Cessation Study …